Menü
sharewise zieht um Am Wochenende vom 22./23. August wird das neue sharewise die Hauptseite. Schau es dir jetzt an und sag uns, was dir fehlt. Zum neuen sharewise Was sich ändert
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Are Medical Stocks Lagging Bayer (BAYRY) This Year?


For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Bayer Aktiengesellschaft (BAYRY) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Bayer Aktiengesellschaft is one of 928 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 9.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, BAYRY has moved about 26.2% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.1%. This means that Bayer Aktiengesellschaft is outperforming the sector as a whole this year.

One other Medical stock that has outperformed the sector so far this year is Align Technology (ALGN). The stock is up 12.5% year-to-date.

For Align Technology, the consensus EPS estimate for the current year has increased 1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, a group that includes 11 individual stocks and currently sits at #200 in the Zacks Industry Rank. This group has gained an average of 1.7% so far this year, so BAYRY is performing better in this area.

Align Technology, however, belongs to the Medical - Dental Supplies industry. Currently, this 15-stock industry is ranked #82. The industry has moved +8.5% so far this year.

Investors with an interest in Medical stocks should continue to track Bayer Aktiengesellschaft and Align Technology. These stocks will be looking to continue their solid performance.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
 
Align Technology, Inc. (ALGN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research


Source Zacks-com

Like: 0
Teilen
At Zacks, we are dedicated to independent investment research, helping investors succeed through tools like our Zacks Rank stock-rating system, which has averaged +23.89% annual returns since 1988. Founded on the discovery that earnings estimate revisions drive stock prices, we offer purely mathematical, unbiased ratings, along with additional innovations like the Price Response Indicator, Earnings ESP, and specialized rankings for mutual funds and ETFs.
...
Rechtlicher Hinweis

Kommentare